Roth Capital Has Bullish Estimate for Enovis FY2025 Earnings

Enovis Co. (NYSE:ENOV) – Stock analysts at Roth Capital upped their FY2025 earnings per share estimates for shares of Enovis in a research note issued on Wednesday, November 6th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $3.31 per share for the year, up from their previous estimate of $3.03. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis’ FY2026 earnings at $3.99 EPS.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same quarter last year, the business posted $0.56 EPS. The company’s revenue was up 21.0% on a year-over-year basis.

Several other research firms have also recently weighed in on ENOV. JMP Securities initiated coverage on Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price on the stock. Evercore ISI dropped their price objective on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. Needham & Company LLC reissued a “buy” rating and set a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $67.00.

Enovis Stock Performance

Shares of ENOV stock opened at $46.91 on Monday. The stock’s fifty day simple moving average is $42.29 and its 200-day simple moving average is $45.32. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of -21.42 and a beta of 1.91. The company has a current ratio of 2.27, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Enovis has a 1-year low of $38.27 and a 1-year high of $65.03.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently modified their holdings of the business. Swiss National Bank raised its holdings in Enovis by 0.3% during the first quarter. Swiss National Bank now owns 97,000 shares of the company’s stock valued at $6,058,000 after buying an additional 300 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after purchasing an additional 371 shares during the last quarter. Pitcairn Co. boosted its position in Enovis by 6.8% during the first quarter. Pitcairn Co. now owns 6,036 shares of the company’s stock worth $377,000 after purchasing an additional 386 shares during the period. Aigen Investment Management LP grew its holdings in Enovis by 5.1% during the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock valued at $381,000 after purchasing an additional 430 shares during the last quarter. Finally, Keeley Teton Advisors LLC lifted its stake in shares of Enovis by 6.8% in the first quarter. Keeley Teton Advisors LLC now owns 6,936 shares of the company’s stock worth $433,000 after buying an additional 441 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.